We are devoted to providing the most comprehensive and
accurate molecular diagnostic information for every cancer
patient and for physicians to help patients get
personalized treatment.
We collaborate with hospitals and
institutes by providing
comprehensive genomic testing in
our CLIA-certificated and CAP-
accredited laboratory.
We partner with pharmaceutical
companies all over the world throughout
research, biomarker-driven drug
development and commercialization of
new cancer therapies.
As one of the largest genomic
datasets in China, we build datasets
of Chinese cancer patients to
advance medical research and new
drug development.
We have integrated DNA and RNA sequencing results
for detection of fusion genes with higher sensitivity.
We have leveraged multiple techniques (DNA, RNA,
IHC, etc.) to help identify immunotherapy-related
biomarkers for our patients.
OrigiMed has 43,000 square feet of lab
space which has been built in line with
international standards and 54,000 sq.ft
of office space.
43,000 sq.ftLab Space
4PBStorage Capacity
110 TFLOPSTotal Peak Performance
2,304 CoresCPU Core Number
20.4 TBTotal Memory
CAP-accredited
by The College of
American Pathologists
CLIA-certificated
by The Centers for
Medicare & Medicaid
Service
NIH/CPTAC
Collaboration
CSCO-OrigiMed Cancer
Genomics Data
Platform for Chinese
cancer patients
CTONG-OrigiMed
New Clinical Trial
Sharing Platform
